Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 19/20 | 0.52 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.52 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.52 |
| ▸ | DMPK | Q09013 | 1/20 | 0.52 |
| ▸ | EPHA7 | Q15375 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937631 | 0.95 | MAP3K12 (0.54) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL19937608 | 0.83 | MAP3K12 (0.52) | MAP3K12TNF | |
| SCHEMBL19937617 | 0.81 | MAP3K12 (0.50) | MAP3K12 | |
| SCHEMBL19937780 | 0.81 | MAP3K12 (0.52) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL19937851 | 0.81 | MAP3K12 (0.51) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL19937816 | 0.79 | MAP3K12 (0.52) | MAP3K12TNF | |
| SCHEMBL19937787 | 0.79 | MAP3K12 (0.54) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL19937997 | 0.79 | MAP3K12 (0.52) | MAP3K12 | |
| SCHEMBL19937750 | 0.78 | MAP3K12 (0.55) | MAP3K12 | |
| SCHEMBL19936821 | 0.78 | MAP3K12 (0.52) | MAP3K12MAP3K13NTRK1CSF1RAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | disclosed |